期刊文献+

腹膜后平滑肌肉瘤11例临床及病理分析 被引量:11

Primary retroperitoneal leiomyosarcoma: a clinical and pathological study of 11 cases
原文传递
导出
摘要 目的 探讨腹膜后平滑肌肉瘤患者的临床病理特点及治疗方法.方法 回顾性分析1994年11月至2014年8月我院收治的11例腹膜后平滑肌肉瘤患者的临床资料.男5例,女6例.年龄13~75岁,中位年龄50岁.以血尿、腹部包块、腹部疼痛等为主要表现.CT平扫可见肿物呈软组织密度,内部密度不均,增强后肿物不同程度强化.手术标本行常规HE染色及免疫组化染色检查.结合患者临床特征及影像学表现,对腹膜后平滑肌肉瘤的临床病理特征进行分析.结果 11例患者均行手术治疗.术后病理示肿瘤直径中位数为14.4 cm.病理均提示出血坏死,镜下均呈梭形细胞排列,细胞密集,细胞核有异型,核分裂象易见.术后化疗2例,放疗1例.随访3例,分别于术后2个月、3年、5年复发.结论 腹膜后平滑肌肉瘤致死率高、复发率高,临床与CT表现均无特异性,确诊仍需依靠病理组织学与免疫组化检查. Objective To analyze the clinical characteristics,pathology,CT characteristics and targeted therapy of primary retroperitoneal leiomyosarcoma treated at our institution during the past 20 years.Methods A retrospective review was performed among 11 patients of this disease.The main performances were hematuria,abdominal mass and abdominal pain.Non-enhanced CT scanning showed soft tissue density in all cases.Tri-phase enhanced scanning showed reinforcement in different degrees.Pathology results showed tissue necrosis.The pathology featured by routine HE and immumohistochemical staining.Results Surgical treatment was performed in all 11 patients.Postoperative pathology showed that median tumor diameter was 14.40cm.Spindle cell,cellular abnormity and mitotic figures could be seen through light microscope.During follow-up,3 cases recurrenced after 2 months,3 years and 5 years respectively.Conclusions Primary retroperitoneal leiomyosarcoma might have a high fatality rate and high recurrence rate.The clinical and CT features are unapparent.Pathology diagnosis is reliable,surgery is necessary to prolong life and cure disease.
作者 王关卉儿 何廉波 杨恺惟 王子成 程立 林健 Wang Guanhuier He Lianbo Yang Kaiwei Wang Zicheng Cheng Li Lin Jian(Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing 100034, China)
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2016年第12期916-919,共4页 Chinese Journal of Urology
关键词 腹膜后肿瘤 平滑肌肉瘤 病理 Retroperitoneal neoplasms Leiomyosarcoma Pathology
  • 相关文献

参考文献1

二级参考文献12

  • 1Motzer RJ, Michaelson MD, Redman BG, et ai. Activity of SU 11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platetel derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24:16- 24.
  • 2National Cancer Institute Common Terminology Criteria for adverse events Version 3. 0 http://ctep, cancer, gov/protocolDevelopment/electronic_applications/docs/ctcaev3, pdf.
  • 3Motzer RJ, Bacik J, Murphy BA, et al. Interferon alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol, 2002,20:289- 296.
  • 4Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med, 2007, 356:115 -124.
  • 5Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009, 27:3584 -3590.
  • 6Motzer RJ, Bacik J, Murphy BA, et al. Interferon alfa as a comparative treatment for clinical trials of new therapies a gainst advanced renal cell carcinoma. J Clin Oncol, 2002, 20: 289 -296.
  • 7Coppin C, Porzsolt F, Awa A, et al. Ingnunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev, 2006, 1- 65.
  • 8Hong MH, Kim HS, Kim C, et al. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat, 2009, 41: 67-72.
  • 9Lee S, Chung HC, Mainwaring P, et al. An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma. Eur J Cancer Supple, 2009, 7: 428.
  • 10Uemura H, Shinohara N, Yuasa T, et al. A phase II study of sunitinib in Japanese patients with Metastatic Renal Cell Careinoma: Insights into the Treatment Efficacy and Safety. JapaneseJ clin. Oncol, 2010, 40: 194- 200.

共引文献14

同被引文献28

引证文献11

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部